Cronos Australia Ltd. (AU:VIT)
ASX:VIT
Want to see AU:VIT full AI Analyst Report?
VIT Stock Chart & Stats
AU$0.06
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.06
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.08
Previous CloseN/A
Volume1.00K
Average Volume (3M)228.84K
Market Cap
AU$24.52M
Enterprise ValueAU$34.44M
Total Cash (Recent Filing)AU$6.10M
Total Debt (Recent Filing)AU$17.34M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.28%
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding662,741,800
10 Day Avg. Volume238,134
30 Day Avg. Volume228,844
Financial Highlights & Ratios
PEG Ratio-1.01
Price to Book (P/B)0.78
Price to Sales (P/S)0.30
P/FCF Ratio14.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Leverage And Strong Equity BaseA low debt-to-equity (0.25) and a 63.85% equity ratio indicate a conservatively financed balance sheet. This durable capital structure reduces refinancing risk, supports investment or R&D through downturns, and provides flexibility to fund strategic initiatives without heavy leverage.
Stable Gross Profit Margin Indicating Cost ControlA 27.21% gross margin shows structural ability to manage production and input costs versus revenue. Sustained product-level margins support long-term profitability potential, enabling the firm to withstand pricing pressure and invest in product or market development over multiple quarters.
High Free Cash Flow Conversion Of Net IncomeConverting near parity (0.97) of net income into free cash flow demonstrates an ability to turn earnings into discretionary cash. Over the medium term this supports dividend payments, operational funding and reduces reliance on external financing despite recent absolute FCF volatility.
Bears Say
Severe Deterioration In Free Cash Flow GrowthA collapse in free cash flow growth (-2056%) and an OC/NI ratio of 0.14 signal persistent cash-generation weakness. This is a durable concern: limited internal cash constrains capex, R&D, debt servicing and dividend sustainability and may force external funding.
Negative Revenue Growth / Top-line ContractionA decline in revenue (-2.0%) undermines scalability and long-run margin expansion. Persistent top-line weakness reduces operating leverage benefits, pressures per-unit economics and limits the company’s ability to recuperate fixed costs, constraining sustainable profit growth.
Sharp Earnings Deterioration (EPS Decline)A steep EPS decline (~-64.7%) reflects weakening core profitability or one-off items that materially reduced earnings power. This hurts retained earnings, limits internal funding for strategic initiatives and raises the hurdle for management to restore consistent long-term earnings growth.
Cronos Australia Ltd. News
VIT FAQ
What was Cronos Australia Ltd.’s price range in the past 12 months?
Cronos Australia Ltd. lowest share price was AU$0.04 and its highest was AU$0.07 in the past 12 months.
What is Cronos Australia Ltd.’s market cap?
Cronos Australia Ltd.’s market cap is AU$24.52M.
When is Cronos Australia Ltd.’s upcoming earnings report date?
Cronos Australia Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 135 days.
How were Cronos Australia Ltd.’s earnings last quarter?
Cronos Australia Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.001.
Is Cronos Australia Ltd. overvalued?
According to Wall Street analysts Cronos Australia Ltd.’s price is currently Overvalued.
Does Cronos Australia Ltd. pay dividends?
Cronos Australia Ltd. pays a Annually dividend of AU$0.002 which represents an annual dividend yield of 3.28%. See more information on Cronos Australia Ltd. dividends here
What is Cronos Australia Ltd.’s EPS estimate?
Cronos Australia Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cronos Australia Ltd. have?
Cronos Australia Ltd. has 662,741,800 shares outstanding.
What happened to Cronos Australia Ltd.’s price movement after its last earnings report?
Cronos Australia Ltd. reported an EPS of -AU$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.167%.
Which hedge fund is a major shareholder of Cronos Australia Ltd.?
Currently, no hedge funds are holding shares in AU:VIT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cronos Australia Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.51%
12-Months-Change
Fundamentals
Return on Equity
1.66%
Trailing 12-Months
Asset Growth
8.56%
Trailing 12-Months
Company Description
Cronos Australia Ltd.
Vitura Health Limited engages in the sale and distribution of medicinal cannabis products in Australia and Asia. Its brands include CanView, Burleigh Heads Cannabis, CDA Clinics, Cannadoc, and Adaya. The company was formerly known as Cronos Australia Limited and changed its name to Vitura Health Limited in February 2023. The company was incorporated in 2018 and is based in South Yarra, Australia.
Technical Analysis
Elixinol Wellness
―
Cann Group
―
Epsilon Healthcare Limited
―
Little Green Pharma Ltd.
―
―